Journal of Neurology

, Volume 255, Supplement 1, pp 3–11 | Cite as

A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis

Article

Abstract

Multiple sclerosis is postulated to be a T cell-mediated autoimmune disease characterised by a relapsing-remitting stage followed by a secondary progressive phase. The relapsing remitting phase may involve waves of proinflammatory Th1 and Th17 cells that infiltrate the nervous system, provoking a clinical attack. The activity of these cells is modulated by other populations of regulatory T cells and the balance between the pro-inflammatory and regulatory T cells is critical for determining disease activity. Promoting the activity of regulatory cells is a potentially beneficial therapeutic strategy, and probably contributes to the action of glatiramer acetate. The progressive phase of multiple sclerosis is believed to be secondary to neurodegenerative changes triggered by inflammation. The status of the innate immune system and its relationship to the stages of multiple sclerosis has been poorly defined until recently. However, recent data suggest that these results demonstrate abnormalities of dendritic cell activation or maturation may underlie the transition to the progressive phase of the disease. Preventing this transition, perhaps by acting at the level of the innate immune system, is an important treatment goal. The identification of biomarkers to predict disease course and treatment response is a major challenge in multiple sclerosis research. Studies using antigen arrays have identified antibody patterns related to CNS antigens and heat-shock proteins that are associated with different disease stages and with response to therapy. In the future, such antibody repertoires could be used as biomarkers for the diagnosis and evaluation of patients with multiple sclerosis, for matching treatments to individual patients and, potentially, to identify healthy individuals at risk for this autoimmune disease.

Key words

Multiple sclerosis immune system inflammation T-cell regulatory cells innate immune system neurodegeneration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bakshi R, Neema M, Liptak S, Betensky R, Buckle G, Gauthier S, Stankiewicz J, Meier D, Egorova S, Arora A, Dandamudi V, Batt C, Guss Z, Glanz B, Khoury S, Guttmann C, Weiner H (2007) Magnetic Resonance Disease Severity Scale (MRDSS) Predicts Clinical Progression in Multiple Sclerosis. Neurology 68(Suppl 1):A53CrossRefGoogle Scholar
  2. 2.
    Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL (1997) Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proceedings of the National Academy of Sciences of the United States of America 94:599–603PubMedCrossRefGoogle Scholar
  3. 3.
    Basso A, Frenkel D, Petrovic-Stojkovic S, Puckett L, Monsonego A, Gozin M, Weiner H (2007) Fullerene (ABS-75) Treatment Reduces Disease Progression and Axonal Loss in MOG-Induced Progressive EAE in NOD Mice. Neurology 68(Suppl 1):A317Google Scholar
  4. 4.
    Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238PubMedCrossRefGoogle Scholar
  5. 5.
    Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, Tolkoff-Rubin N, Rubin RH, Herrin JT, Russell PS (1981) Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32:535–539PubMedCrossRefGoogle Scholar
  6. 6.
    Dyment DA, Ebers GC, Sadovnick AD (2004) Genetics of multiple sclerosis. Lancet Neurology 3:104–110PubMedCrossRefGoogle Scholar
  7. 7.
    Gauthier S, Liptak S, Polgar-Turcsanyi M, Berger A, Glanz B, Buckle G, Khoury S, Weiner H, Bakshi R, Guttmann C (2007) Benign MS characterized by a lower rate of brain atrophy as compared to early MS. Neurology 68(Suppl 1):A330–A331Google Scholar
  8. 8.
    Gauthier SA, Glanz BI, Mandel M, Weiner HL (2006) A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmunity Reviews 5:532–536PubMedCrossRefGoogle Scholar
  9. 9.
    Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL (2007) Risk alleles for multiple sclerosis identified by a genomewide study. The New England Journal of Medicine 357:851–862PubMedCrossRefGoogle Scholar
  10. 10.
    Harbo HF, Spurkland A (2007) Genetics in multiple sclerosis: past and future perspectives. Acta Neurol Scand (Suppl 187:)34–38Google Scholar
  11. 11.
    Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA (2002) Anti-CD3 monoclonal antibody in newonset type 1 diabetes mellitus. The New England Journal of Medicine 346:1692–1698PubMedCrossRefGoogle Scholar
  12. 12.
    Hong J, Li N, Zhang X, Zheng B, Zhang JZ (2005) Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proceedings of the National Academy of Sciences of the United States of America 102:6449–6454PubMedCrossRefGoogle Scholar
  13. 13.
    Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL (2007) Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 56:2103–2109PubMedCrossRefGoogle Scholar
  14. 14.
    Karni A, Abraham M, Monsonego A, Cai G, Freeman GJ, Hafler D, Khoury SJ, Weiner HL (2006) Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 177:4196–4202PubMedGoogle Scholar
  15. 15.
    Karni A, Koldzic DN, Bharanidharan P, Khoury SJ, Weiner HL (2002) IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions. J Neuroimmunol 125:134–140PubMedCrossRefGoogle Scholar
  16. 16.
    Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T, Wekerle H, Hohlfeld R (2000) Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proceedings of the National Academy of Sciences of the United States of America 97:7452–7457PubMedCrossRefGoogle Scholar
  17. 17.
    Ochi H, Abraham M, Ishikawa H, Frenkel D, Yang K, Basso AS, Wu H, Chen ML, Gandhi R, Miller A, Maron R, Weiner HL (2006) Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25– LAP+ T cells. Nature Medicine 12:627–635PubMedCrossRefGoogle Scholar
  18. 18.
    Putheti P, Soderstrom M, Link H, Huang YM (2003) Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol 144:125–131PubMedCrossRefGoogle Scholar
  19. 19.
    Quintana F, Viglietta V, Cohen I, Khoury S, Weiner H (2007) Antigen microarrays identify serum biomarkers for multiple sclerosis. Neurology 68(Suppl 1):A399Google Scholar
  20. 20.
    Ramsaransing GS, De Keyser J (2006) Benign course in multiple sclerosis: a review. Acta Neurol Scand 113:359–369PubMedCrossRefGoogle Scholar
  21. 21.
    Rasmussen S, Imitola J, Khoury S (2007) Cortical multiple sclerosislike lesions with persistent microglial activation and neuronal dysfunction in EAE. Neurology 68(Suppl 1):A315CrossRefGoogle Scholar
  22. 22.
    Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. The Journal of Experimental Medicine 199:971–979PubMedCrossRefGoogle Scholar
  23. 23.
    Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24:677–688PubMedCrossRefGoogle Scholar
  24. 24.
    Wilde MI, Goa KL (1996) Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 51:865–894PubMedCrossRefGoogle Scholar
  25. 25.
    Ziemssen T, Schrempf W (2007) Glatiramer acetate: mechanisms of action in multiple sclerosis. International Review of Neurobiology 79:537–570PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2008

Authors and Affiliations

  1. 1.Center for Neurologic Diseases, Dept. of Neurology Brigham and Women's HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations